Abad-Esteve A, Rosell R, Moreno I, Serichol M, Moya L, Ribas-Mundo M
Department of Medicine, Hospital de Badalona Germans Trias i Pujol, Barcelona, Spain.
Oncology. 1989;46(4):235-7. doi: 10.1159/000226723.
The antiemetic effect of a new benzamide, alizapride, was investigated with escalating doses through four levels starting at 5 mg/kg/cycle up to 20 mg/kg/cycle. 39 patients were accrued who received cancer chemotherapy which included the following drugs in various combinations: cyclophosphamide, adriamycin, fluorouracil, carboplatin and etoposide (VP-16). Complete control of emesis was achieved in a third of the 39 patients. There was no statistically significant difference among the dose levels with regard to the patient's assessment of the incidence and severity of nausea and vomiting. Alizapride was well tolerated at all dose levels tested with minimal toxicity. Mild sedation was reported in 60% of the patients. Neither extrapyramidal reactions nor hypotensive side effects were observed. Thus the therapeutic yield of alizapride could be further studied concerning the optimal dose and schedule as well as its use in combination with other antiemetic drugs.
研究了一种新型苯甲酰胺类药物阿立必利的止吐效果，通过四个剂量水平逐步递增给药，起始剂量为5毫克/千克/周期，最高至20毫克/千克/周期。共招募了39名接受癌症化疗的患者，化疗药物包括以下几种不同组合：环磷酰胺、阿霉素、氟尿嘧啶、卡铂和依托泊苷（VP - 16）。39名患者中有三分之一实现了呕吐的完全控制。在患者对恶心和呕吐的发生率及严重程度的评估方面，各剂量水平之间没有统计学上的显著差异。在所有测试剂量水平下，阿立必利耐受性良好，毒性极小。60%的患者报告有轻度镇静作用。未观察到锥体外系反应或低血压副作用。因此，关于阿立必利的最佳剂量和给药方案以及与其他止吐药物联合使用的治疗效果，还有待进一步研究。
